Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 11—November 2018
Dispatch

Ehrlichia Infections, North Carolina, USA, 2016

Ross M. BoyceComments to Author , Alan M. Sanfilippo, John M. Boulos, Meghan Cleinmark, John Schmitz, and Steve Meshnick
Author affiliations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

Main Article

Table

Patient characteristics stratified by provider-ordered Ehrlichia testing, North Carolina, 2016*

Characteristic Tested for Ehrlichia, no. (%), n = 70† Not tested for Ehrlichia, no. (%), n = 124† p value
Sex



M
39 (55.7)
64 (52.0)
0.48
F
31 (44.2)
60 (48.0)

Setting 0.09
Outpatient clinic 42 (63.4) 57 (48.3)
Emergency department 16 (24.2) 47 (39.8)
Inpatient
8 (12.1)
14 (11.9)

Provider medical specialty 0.001
Emergency medicine 13 (18.8) 43 (34.7)
Family medicine 16 (23.2) 20 (16.1)
Infectious diseases 9 (13.0) 2 (1.6)
Internal medicine 15 (21.7) 18 (14.5)
Other
16 (23.2)
41 (33.1)

Reported signs and symptoms
Fever 27 (38.6) 47 (37.9) 0.93
Headache 22 (31.4) 32 (25.8) 0.40
Myalgia 11 (15.7) 31 (25.0) 0.13
Rash
12 (17.1)
27 (21.8)
0.44
Tick exposure‡
28 (41.2)
33 (27.7)
0.05
Testing
SFGR 62 (88.6) 92 (74.2) 0.02
Lyme disease
48 (68.6)
80 (64.5)
0.57
Positive test result
Ehrlichia 9 (12.9) 25 (20.2) 0.20
SFGR 15 (24.2) 22 (23.9) 0.97
Lyme disease
0 (0.0)
1 (1.3)
0.44
Doxycycline prescribed
27 (39.7)
67 (55.8)
0.03
Convalescent-phase serology performed 15 (21.7) 10 (8.1) 0.007

*Boldface indicates significance at p<0.05. IQR, interquartile range; SFGR, spotted fever group Rickettsia.
†Among those tested for Ehrlichia, median (IQR) age was 53.5 (33–67) y, and among those not tested for Ehrllichia, median (IQR) age was 46 (30–61.5) y (p = 0.48). Among those tested for Ehrlichia, duration of symptoms was 6.5 (3–14) d, and among those not tested for Ehrlichia, duration was 5.5 (3–14) d (p = 0.59). Numbers and percentages vary because some data were not available.
‡Unable to determine exposure status for 24 (35.3%) of 68 patients tested for Ehrlichia and 64 (53.8%) of 119 patients not tested for Ehrlichia.

Main Article

Page created: October 17, 2018
Page updated: October 17, 2018
Page reviewed: October 17, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external